Yan Weng, Kari R Fonseca, Yi-An Bi, Sumathy Mathialagan, Keith Riccardi, Elaine Tseng, Andrew J Bessire, Matthew A Cerny, David A Tess, A David Rodrigues, Amit S Kalgutkar, John E Litchfield, Li Di, Manthena V S Varma
Excess dietary fructose consumption promotes metabolic dysfunction thereby increasing the risk of obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH), and related comorbidities. PF-06835919, a first-in-class ketohexokinase (KHK) inhibitor, showed reversal of such metabolic disorders in preclinical models and clinical studies, and is under clinical development for the potential treatment of NASH. In this study, we evaluated the transport and metabolic pathways of PF-06835919 disposition and assessed pharmacokinetics in preclinical models...
July 2, 2022: Drug Metabolism and Disposition: the Biological Fate of Chemicals